Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06271941

Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps

Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2024-11-25

892

Participants Needed

1

Research Sites

26 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating new techniques to reduce the recurrence of large colorectal polyps, which can be precursors to colorectal cancer. The trial focuses on patients with large laterally spreading lesions (LSLs) of at least 20mm, which are treated via endoscopic mucosal resection (EMR). The study compares two ablation methods used after EMR to prevent polyp regrowth: hybrid argon plasma coagulation (h-APC) and snare tip soft coagulation (STSC). Participants will be randomly assigned to one of two groups after the initial EMR procedure. One group will receive additional h-APC to ablate both the margin and base of the polypectomy site, while the other group will receive STSC margin ablation only. The EMR involves lifting the polyp with a submucosal injection, followed by snare electrocautery resection. If multiple polyps are present, the study polyp will be marked for follow-up. Follow-up includes colonoscopies and biopsies at 6 months and approximately 18 months to check for recurrence. During the study, participants undergo colonoscopy preparation before the procedure and receive the assigned ablation treatment during EMR. Telephone follow-up occurs 14 days post-procedure to monitor for adverse events. Subsequent colonoscopies assess polyp recurrence, with additional treatment if recurrence is detected. Researchers will measure recurrence rates, adverse events, technical success of ablation, and occurrence of high-grade dysplasia or colorectal cancer over a 4-year period.

CONDITIONS

Brief Title

Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult 18 years or older
  • Undergoing endoscopic mucosal resection (EMR) for a large (≥20mm) colorectal laterally spreading lesion (LSL)
  • Providing written and informed consent for study participation
Not Eligible

You will not qualify if you...

  • Inflammatory bowel disease
  • Non-elective colonoscopy
  • Poor general health (American Society of Anesthesiologists classification >III)
  • Coagulopathy or thrombocytopenia (INR ≥1.5 or platelets <50 x 10^9/L)
  • Pedunculated polyps (Paris class Ip, Isp)
  • Overt signs of deep submucosal invasive cancer (JNET 3)
  • Biopsy-proven invasive carcinoma in a potential study polyp
  • Pregnant women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Screening and enrollment visit

Treatment

Duration - Day of EMR procedure

Participants undergo endoscopic mucosal resection (EMR) for removal of large colorectal polyps, followed by randomized margin ablation with either hybrid argon plasma coagulation (h-APC) or snare tip soft coagulation (STSC).

1 procedure visit (in-person)

Post-operative Follow-up

Duration - 14 days after EMR

Participants receive a telephone call 14 days after EMR to assess for any adverse events following the procedure.

1 telephone follow-up

Surveillance

Duration - 6 months and approximately 18 months after EMR

Participants undergo surveillance colonoscopies to assess for polyp recurrence at the EMR site, including biopsies for pathology confirmation.

2 colonoscopy visits (in-person)

Trial Site Locations

Total: 1 location

1

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

A Phase 1/2a Study of the Safety, Tolerability, and Prelimin...

Castration-Resistant Prostate Cancer (CRPC)

Actively Recruiting

4 locations

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabe...

Metastatic Sarcoma

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here